Virgo Carter Pediatrics — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$487	3
2024	Research	$1,500	1
2023	Research	$3,996	4
2022	Research	$6,210	4
2021	Research	$33,442	2
2020	Research	$9,711	17
2019	Research	$10,084	20

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $51,796 35 payments
AbbVie, Inc. $10,206 8 payments
GlaxoSmithKline, LLC. $1,500 1 payment
Teva Pharmaceuticals USA, Inc. $1,206 1 payment
Pfizer Inc. $487 3 payments
Allergan Inc. $235 3 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $47,552 9 payments
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) $6,486 4 payments
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $3,102 19 payments
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children $1,608 2 payments
A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Study to $1,500 1 payment
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age $1,206 1 payment
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension $1,188 1 payment
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED $1,142 7 payments
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide $924 1 payment
A Phase 2 Randomized Doubleblind Trial to Evaluate the Safety Tolerability and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants $487 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.